Vitamin D metabolism in myeloma.
We measured serum concentrations of vitamin D metabolites in 27 patients with myeloma, 16 of whom were hypercalcaemic. Serum values were compared with values from normal controls. Serum concentrations of calcitriol (1.25-dihydroxyvitamin D; 1.25(OH)2D3) were decreased in both hyper- and normocalcaemic patients, but more markedly so in hypercalcaemia. These findings were not solely due to impaired renal function nor due to an inadequate supply of 25-hydroxyvitamin D, and in hypercalcaemic patients were reversed by diphosphonate treatment. We conclude that hypercalcaemia in myeloma is not mediated by abnormalities in vitamin D metabolism. Decreased serum concentrations of 1.25(OH)2D3 may adversely affect both skeletal and tumour metabolism.
Lawson-Matthew
P
P
Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School.
Clayton
J
J
Guilland-Cumming
D
D
Yates
A
A
Preston
E
E
Greaves
M
M
Kanis
J A
JA
D000328:Adult; D000368:Aged; D002117:Calcitriol / Q000097:blood; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications / Q000378:metabolism*; D014807:Vitamin D / Q000378:metabolism*
D014807:Vitamin D; D002117:Calcitriol